Leading US cancer researcher failed to disclose industry ties in dozens of articlesBMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3868 (Published 11 September 2018) Cite this as: BMJ 2018;362:k3868
- Owen Dyer
- Montreal, Canada
One of America’s most prominent breast cancer doctors failed to disclose pharmaceutical industry ties worth millions of dollars in authoring dozens of articles in major journals, according to a report by the New York Times and ProPublica.
José Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center in New York City, neglected to mention multiple directorships and consultancy fees when completing conflict of interest disclosure forms for leading publications including the New England Journal of Medicine and the Lancet, the report found.
Baselga also left out his industry payments when writing for Cancer Discovery, the journal of the American Association for Cancer Research (AACR), even though he was the joint editor-in-chief and president of the association.
“I acknowledge that there have been inconsistencies, but that’s what it is,” he told the New York Times and ProPublica investigative team, asking their opinion on how he should solve the problem. “It’s not …